VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

As previously reported, Wedbush analyst Robert Driscoll downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Shares in US biotech Arvinas were more than 50% lower, and those in pharma giant Pfizer down 2%, at the mid-point of ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...